Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 1, 2012, Pages 31-42

  Parente, Phillip ^a,b   Parnis, Francis ^c   Gurney, Howard ^d  

^a BOX HILL HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Adelaide Cancer Centre   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Abiraterone acetate; Cabazitaxel; Innovative therapy; Prostate cancer; Sipuleucel T

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; BICALUTAMIDE; BOSUTINIB; CABAZITAXEL; CABOZANTINIB; DASATINIB; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; IPILIMUMAB; LEUPRORELIN; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; SAMARIUM 153; SARACATINIB; SATRAPLATIN; SIPULEUCEL T; STRONTIUM 89; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPETITIVE INHIBITION; DIARRHEA; DRUG DOSE COMPARISON; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; METASTASIS; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; VERTEBRA FRACTURE; VISCERAL METASTASIS;

EID: 84857527257     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01506.x     Document Type: Review

References (69)

1. Australian Institute of Health and Welfare and Australian Association of Cancer Registries. Cancer in Australia: An Overview 2010. AIHW, Canberra 2011. Report No.: Cancer Series Number 60.
2. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007; 82: 243-9.
3. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21: 260-5.
4. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-41.
5. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (Suppl):1098-109.
6. Tannock IF, Osoba D, Stockler MR etal. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
7. Kantoff PW, Halabi S, Conaway M etal. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
8. Petrylak DP, Tangen CM, Hussain MH etal. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
9. Tannock IF, de Wit R, Berry WR etal. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
10. Scher HI, Halabi S, Tannock I etal. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
11. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70: 983-1000.
12. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010; 5: 395-402.
13. Kantoff PW, Higano CS, Shore ND etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
14. de Bono JS, Oudard S, Ozguroglu M etal. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
15. National Comprehensive Cancer Network. Practice guidelines in oncology: prostate cancer. 2011. Report No.: Version 1.
16. Small EJ, Schellhammer PF, Higano CS etal. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94.
17. Higano CS, Schellhammer PF, Small EJ etal. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9.
18. Chambers JD, Neumann PJ. Listening to Provenge - what a costly cancer treatment says about future Medicare policy. N Engl J Med 2011; 364: 1687-9.
19. Jankovic B, Beardsley E, Chi K. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis. Presented at ASCO Genitourinary Cancers Symposium; February 14-16, San Francisco, CA. Abstract 196. 2008.
20. Ansari MS, Choo CM, Hussain M. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: an updated analysis. Presented at ASCO Genitourinary Cancers Symposium; February 26-29; Orlando, FL. Abstract 185. 2009.
21. Loriot Y, Massard C, Gross-Goupil M etal. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46: 1770-2.
22. Eymard JC, Oudard S, Gravis G etal. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 974-8.
23. Di Lorenzo G, Buonerba C, Faiella A etal. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011; 107: 234-9.
24. Colloca G, Venturino A, Checcaglini F. Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review. Med Oncol 2011; 21 February [Epub ahead of print].
25. Sternberg CN, Petrylak DP, Sartor O etal. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.
26. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006; 54: 72-84.
27. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001; 7: 1251-7.
28. De Bono JS, Oudard S, Ozguroglu M etal. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011; 29 (Suppl): Abstract 4526.
29. Mita AC, Denis LJ, Rowinsky EK etal. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-30.
30. Pivot X, Koralewski P, Hidalgo JL etal. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19: 1547-52.
31. 2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA). Study NCT01308580. 2011. [cited 16 Aug 2011]. Available from: .
32. NIH Clinical Trials Database. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). Study NCT01308567. 2011. [cited 16 Aug 2011]. Available from: .
33. Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185: 787-94.
34. Reid AH, Attard G, Danila DC etal. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95.
35. Danila DC, Morris MJ, De Bono JS etal. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501.
36. De Bono JS, Logothetis CJ, Molina A etal. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
37. NIH Clinical Trials Database. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. NCT00887198; 2009. [cited 16 Aug 2011]. Available from: .
38. NIH Clinical Trials Database. Abiraterone acetate in treating patients with prostate cancer who have undergone initial hormone therapy. Study NCT01309672; 2011. [cited 16 Aug 2011]. Available from: .
39. NIH Clinical Trials Database. IMAAGEN: impact of abiraterone acetate in prostate-specific antigen. Study NCT01314118; 2011. [cited 16 Aug 2011]. Available from: .
40. NIH Clinical Trials Database. Maximum androgen depletion. Study NCT01254864: 2010. [cited 16 Aug 2011]. Available from: .
41. NIH Clinical Trials Database. Study of abiraterone acetate in patients with advanced prostate cancer. Study NCT01217697. 2011. [cited 16 Aug 2011]. Available from: .
42. NIH Clinical Trials Database. Abiraterone post ketoconazole. Study NCT01199146. 2010. [cited 16 Aug 2011]. Available from: .
43. NIH Clinical Trials Database. Neo-adjuvant abiraterone+luteinizing hormone-releasing hormone (LHRH) versus LHRH in prostate cancer. Study NCT01088529. 2010. [cited 16 Aug 2011]. Available from: .
44. NIH Clinical Trials Database. Abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy in treating patients with localized or locally advanced prostate cancer. Study NCT01023061: 2011. [cited 16 Aug 2011]. Available from: .
45. NIH Clinical Trials Database. Neoadjuvant abiraterone acetate plus leuprolide acetate in men with localized high risk prostate cancer. Study NCT00924469. 2009. [cited 16 Aug 2011]. Available from: .
46. Morgans AK, Smith MR. RANKL-targeted therapies: the next frontier in the treatment of male osteoporosis. J Osteoporos 2011; 2011: 941310. DOI 10.4061/2011/941310 [Epub ahead of print].
47. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011; 29: 3705-14.
48. Smith MR, Egerdie B, Hernandez TN etal. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55.
49. Fizazi K, Carducci M, Smith M etal. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
50. Nilsson S, Larsen RH, Fossa SD etal. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11: 4451-9.
51. Nilsson S, Franzen L, Parker C etal. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94.
52. TM) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPICA). Eur J Cancer 2011; 47 (Suppl. 2): 3. Abstract: 1LBA.
53. NIH Clinical Trials Database. A study of Alpharadin® with docetaxel in patients with bone metastasis from castration-resistant prostate cancer (CRPC). Study NCT01106352. 2010. [cited 1 Nov 2011]. Available from: .
54. Tollefson MK, Karnes RJ, Thompson RH etal. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. Presented at ASCO 2010 Genitourinary Cancers Symposium [Abstract number 168]. 2010.
55. Granberg C, Karnes RJ, Tollefson MK etal. Conversion of advanced prostate cancer to organ-confined minimal residual disease using CTLA-4 blockade (ipilimumab) immunotherapy. Poster presented at ASCO 2010 Genitourinary Cancers Symposium Abstract 33. 2010.
56. NIH Clinical Trials Database. Neoadjuvant ipilimumab in prostate cancer. Study NCT01194271. 2010. [cited 16 Aug 2011]. Available from: .
57. NIH Clinical Trials Database. Study of immunotherapy to treat advanced prostate cancer. Study NCT00861614. 2009. [cited 16 Aug 2011]. Available from: .
58. NIH Clinical Trials Database. Phase 3 study of immunotherapy to treat advanced prostate cancer. Study NCT01057810. 2010. [cited 16 Aug 2011]. Available from:
59. Drake CG. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol 2009; 27: 4035-7.
60. Tran C, Ouk S, Clegg NJ etal. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
61. Scher HI, Beer TM, Higano CS etal. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
62. NIH Clinical Trials Database. Safety and efficacy study of MDV3100 in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy (AFFIRM). Study NCT00974311. 2009. [cited 16 Aug 2011]. Available from: .
63. NIH Clinical Trials Database. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). Study NCT01212991. 2010. [cited 16 Aug 2011]. Available from: .
64. NIH Clinical Trials Database. A study to test if MDV3100 is effective and safe in prostate cancer patients who have never had hormone therapy. Study NCT01302041. 2011. [cited 16 Aug 2011]. Available from: .
65. NIH Clinical Trials Database. A study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer. Study NCT01288911. 2011. [cited 16 Aug 2011]. Available from: .
66. NIH Clinical Trials Database. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Study NCT01193244. 2010. [cited 16 Aug 2011]. Available from: .
67. NIH Clinical Trials Database. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer. Study NCT01193257. 2010. [cited 16 Aug 2011]. Available from: .
68. NIH Clinical Trials Database. Study of TAK-700 in combination with docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Study NCT01084655. 2010. [cited 16 Aug 2011]. Available from: .
69. NIH Clinical Trials Database. Safety and efficacy study of TAK-700 in patients with nonmetastatic castration-resistant prostate cancer and a rising prostate-specific antigen. Study NCT01046916: 2010. [cited 16 Aug 2011]. Available from: .